Should spironolactone be continued in a patient with hepatorenal syndrome presenting as acute kidney injury and massive ascites due to cirrhosis from chronic hepatitis B?

No, spironolactone should be stopped immediately in a patient with HRS-AKI

In hepatorenal syndrome presenting as acute kidney injury (HRS-AKI), diuretics including spironolactone must be discontinued as a first-line intervention, regardless of the presence of massive ascites. This is a critical and non-negotiable step in the management algorithm.

Immediate Management Algorithm for HRS-AKI

When HRS-AKI is diagnosed in cirrhotic patients with ascites, the following sequence must be implemented:

Step 1: Stop All Diuretics Immediately

• Discontinue spironolactone and furosemide as soon as HRS-AKI is suspected or confirmed 1, 2, 1
• This applies to all stages of AKI (Stage 1,2, and 3) 2
• The guideline is explicit: "In cases of severe hyponatremia, acute kidney injury, overt hepatic encephalopathy, or severe muscle spasm, diuretics dose should be reduced or stopped" 1

Step 2: Review and Withdraw Nephrotoxic Agents

• Stop NSAIDs, vasodilators, and any other potentially nephrotoxic medications 2
• This must occur simultaneously with diuretic withdrawal

Step 3: Initiate Albumin and Vasoconstrictor Therapy

• Begin albumin 1 g/kg body weight (up to 100g) on day 1, followed by 20-40 g/day 3, 2
• Start terlipressin (first-line) at 1 mg IV every 4-6 hours, or as continuous infusion at 2 mg/day, escalating to maximum 12 mg/day if no response after 2 days 3, 4
• Alternative: norepinephrine (particularly if patient is in shock or in ICU setting) 3, 4

Why Spironolactone Must Be Stopped

The pathophysiology is clear: HRS-AKI represents severe renal vasoconstriction in the setting of systemic vasodilation. Continuing diuretics in this context:

1. Worsens intravascular volume depletion, further compromising renal perfusion 2
2. Accelerates progression from Stage 1 to Stage 2-3 AKI 2
3. Increases risk of electrolyte abnormalities (hyperkalemia, hyponatremia) that complicate management 1
4. Contradicts the fundamental treatment principle of volume expansion with albumin 3, 2

Managing the Ascites After Diuretic Withdrawal

The concern about massive ascites is understandable, but must be addressed differently:

For Tense Ascites During HRS-AKI Treatment:

• Perform large-volume paracentesis with albumin replacement (6-8 g albumin per liter removed) 1
• This provides symptomatic relief without compromising renal function
• Paracentesis is safer than continuing diuretics in the HRS-AKI setting 1

After HRS-AKI Resolution:

• Only after complete response (serum creatinine returns to within 0.3 mg/dL of baseline) can diuretics be cautiously reintroduced 2
• Restart at lower doses than previously used
• Monitor closely for recurrence (which occurs in up to 70% of cases) 5

Critical Pitfalls to Avoid

1. Do not continue "low-dose" spironolactone thinking it will help with ascites—any dose is contraindicated in active HRS-AKI 2, 1

2. Do not delay diuretic withdrawal while waiting for diagnostic confirmation—if AKI Stage 1 is present (sCr increase ≥0.3 mg/dL within 48 hours), stop diuretics immediately 2

3. Do not use diuretics as a substitute for paracentesis in managing ascites during HRS-AKI treatment 1

4. Do not restart diuretics until HRS-AKI has fully resolved and renal function has stabilized 2

Prognosis and Definitive Management

• HRS-AKI carries 30-50% one-year survival even with treatment 5
• Liver transplantation is the only definitive cure 3, 5, 6
• All patients with HRS-AKI should be evaluated for transplant candidacy immediately 5, 6
• If transplant is not imminent and ascites recurs after HRS resolution, consider TIPS placement as bridge therapy rather than aggressive diuretics 3, 5

The evidence is unequivocal across all major guidelines (EASL, AASLD, KASL, BSG): diuretics must be stopped in HRS-AKI, and the massive ascites should be managed with paracentesis and albumin, not with continued diuretic therapy 1, 3, 2, 1, 6.